Kevin D. Read

Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022

Short-course combination treatment for experimental chronic Chagas disease

Identification and Optimization of Novel Inhibitors of the Polyketide Synthase 13 Thioesterase Domain with Antitubercular Activity

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Targeting N-myristoylation for therapy of B-cell lymphomas

Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and <i>Mycobacterium tuberculosis</i>: Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against<i>Mycobacterium tuberculosis</i>

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides

A novel multiple-stage antimalarial agent that inhibits protein synthesis

C‐reactive protein is essential for innate resistance to pneumococcal infection

Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor

Automated design of ligands to polypharmacological profiles